Physicians' Academy for Cardiovascular Education

Managing hyperkalemia in HF: Navigating the evolving clinical landscape

10' education - May 16, 2022 - Keith C. Ferdinand, MD and Marco Metra, MD

Management of cancer-associated VTE

10' education - May 12, 2022 - Prof. Stavros Konstantinides, MD

Emerging therapies in HCM: The potential role of cardiac myosin inhibitors

10' education - May 4, 2022 - Ahmad Masri, MD and prof. Deepak Bhatt, MD

Potential mechanisms of benefit of icosapent ethyl

10' education - May 3, 2022 - Prof. Chris Packard, PhD

The 3 things you need to know about HCM

10' education - May 3, 2022 - Ahmad Masri, MD and Steve Ommen, MD

Optimizing oral anticoagulation management for patients with AF

10' education - May 3, 2022 - Prof. Robert Storey, MD

The journey from hypothesis to reality on inflammation in CVD

10' education - Apr. 28, 2022 - Prof. Peter Libby, MD and prof. Paul Ridker, MD

Lipid management and the potential role of bempedoic acid

10' education - Apr. 26, 2022 - Rens Reeskamp, MD, PhD

Discussion - CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl

10' education - Apr. 21, 2022 - Prof. Ulrich Laufs, MD, PhD, prof. Chris Packard, PhD and prof. Wouter Jukema, MD, PhD

Exploring the role of icosapent ethyl based on current clinical evidence

10' education - Apr. 21, 2022 - Prof. Wouter Jukema, MD, PhD

IL-6 as therapeutic target in inflammation and CVD

10' education - Apr. 21, 2022 - Prof. Paul Ridker, MD

Long-term efficacy and safety of radiofrequency renal denervation

5' education - Apr. 20, 2022 - Felix Mahfoud, MD

Hemodynamic valve deterioration in transcatheter aortic valves vs. surgical aortic valves

3' education - Apr. 20, 2022 - Megan Coylewright, MD

MI risk is best captured by number of apoB-containing lipoproteins

5' education - Apr. 20, 2022 - Nicolas Marston, MD

A positive view on a negative trial with DOAC after TAVR

3' education - Apr. 19, 2022 - Megan Coylewright, MD

Novel form of CV research with dietary education in the grocery store

3' education - Apr. 13, 2022 - Prof. Eileen Handberg, PhD

EHR-based intervention improves quality care for patients with HF

3' education - Apr. 13, 2022 - Tariq Ahmad, MD

Residual CV risk in patients on statin therapy

10' education - Apr. 13, 2022 - Prof. Alberto Zambon, MD, PhD

A first clinical trial testing the use of an H₂S donor after heart attack

5' education - Apr. 12, 2022 - Marie-Sophie de Koning, MD

Reductions in LVOT gradients, NYHA class and NT-proBNP with cardiac myosin inhibitor in HCM

5' education - Apr. 11, 2022 - Florian Rader, MD

Atrial fibrillation or flutter increases risk of adverse outcomes in HFpEF

Literature - May 17, 2022 - Cikes M et al. - JACC Heart Fail. 2022

If HFpEF patients also have atrial fibrillation and/or flutter, they are at increased risk of HF hospitalization or CV death, as shown by a post-hoc analysis of the PARAGON-HF trial.

Managing hyperkalemia in HF: Navigating the evolving clinical landscape

10' education - May 16, 2022 - Keith C. Ferdinand, MD and Marco Metra, MD
Keith Ferdinand and Marco Metra talk about how to manage comorbidities, optimize RAASi therapy, and improve the long-term care for patients with heart failure.

Keith Ferdinand and Marco Metra talk about how to manage comorbidities, optimize RAASi therapy, and improve the long-term care for patients with heart failure.

PCSK9i reduces MACE regardless of number of metabolic risk factors

Literature - May 16, 2022 - Ostadal P, et al. - Lancet Diabetes Endocrinol. 2022

Alirocumab reduces MACE irrespective of number of metabolic risk factors, but absolute risk reduction increases with the number of metabolic risk factors, in a post-hoc analysis of ODYSSEY OUTCOMES

Icosapent ethyl decreases CVD risk after MI

Literature - May 16, 2022 - Gaba P et al. - J Am Coll Cardiol. 2022

In a subgroup analysis of REDUCE-IT, additional treatment with icosapent ethyl resulted in less ischemic events in statin-treated patients with prior MI.

Management of cancer-associated VTE

10' education - May 12, 2022 - Prof. Stavros Konstantinides, MD
Prof. Konstantinides discusses clinical practice guidelines on anticoagulation for VTE treatment in patients with cancer.

Prof. Konstantinides discusses clinical practice guidelines on anticoagulation for VTE treatment in patients with cancer.

Elevated sLOX-1 levels in ACS patients predict fatal events at 1 year

Literature - May 11, 2022 - Kraler S, et al. - Eur Heart J. 2022

Elevated plasma sLOX-1 levels –observed during acute coronary syndromes (ACS) – predict fatal events beyond both established CV risk factors and the updated GRACE score, in the multicenter SPUM-ACS study.

Time-restricted diet is not more beneficial than calorie restriction alone

Literature - May 9, 2022 - Liu D et al. - N Engl J Med. 2022

Despite its increasing popularity, time-restricted eating did not show more benefits in Chinese obese patients after one year than restricting calories alone.

Long-term and safe reduction of LDL-c levels with bempedoic acid

Literature - May 9, 2022 - Ballantyne CM, et al. - Am J Cardiol. 2022

In a follow-up study of the CLEAR Harmony trial, up to 2.5 years of continuous treatment with bempedoic acid was generally well tolerated and stably decreased LDL-c levels in patients with ASCVD and/or heterozygous familial hypercholesterolemia.

Primary endpoint met in phase III trial with SGLT2i in HFpEF

News - May 9, 2022

A significant reduction in the primary composite endpoint of CV death or worsening HF was reached with dapagliflozin in HF patients with LVEF >40% in the DELIVER phase III trial.

Emerging therapies in HCM: The potential role of cardiac myosin inhibitors

10' education - May 4, 2022 - Ahmad Masri, MD and prof. Deepak Bhatt, MD
Ahmad Masri and prof. Deepak Bhatt explore the newer cardiac myosin inhibitors that go beyond traditional medical management for the treatment of hypertrophic cardiomyopathy (HCM) at the cellular level. Listen to/watch this animated podcast!

Ahmad Masri and prof. Deepak Bhatt explore the newer cardiac myosin inhibitors that go beyond traditional medical management for the treatment of hypertrophic cardiomyopathy (HCM) at the cellular level. Listen to/watch this animated podcast!

Less hospitalizations for recurrent VTE with extended treatment of DOAC

Literature - May 4, 2022 - Pawar A, et al. - JAMA. 2022

An exploratory analysis showed that apixaban as extended treatment (>90 days) after hospitalization for venous thromboembolism (VTE) is associated with a lower rate of hospitalizations for recurrent VTE versus warfarin as extended treatment.

Potential mechanisms of benefit of icosapent ethyl

10' education - May 3, 2022 - Prof. Chris Packard, PhD
Prof. Packard shares some thoughts on the potential mechanisms of benefit of icosapent ethyl as seen in the REDUCE-IT trial.

Prof. Packard shares some thoughts on the potential mechanisms of benefit of icosapent ethyl as seen in the REDUCE-IT trial.